Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer

NCT01015521 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2010-11-03

No results posted yet for this study

Summary

This is a phase II study to assess the efficacy of Aminoflavone prodrug in triple negative and ER+ breast cancer.

Conditions

  • Breast Neoplasm

Interventions

DRUG

Aminoflavone Prodrug

Aminoflavone Prodrug administered D1, D8 of 21-day cycle

Sponsors & Collaborators

  • Tigris Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2012-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01015521 on ClinicalTrials.gov